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Osteoporosis is a major public health problem becoming
increasingly important as our population ages. Approxi-
mately one in two women will experience an osteoporotic
fracture in their lifetime. Additionally, millions have low
bone mass that increases fracture risk. OBJECTIVE: To
develop a methodology, in a managed care environment,
that identifies members at high-risk for osteoporotic frac-
tures. METHODS: This was a retrospective database
study. The study population was from a Midwest health
plan of 1.38 million lives. The database consisted of all
pharmaceutical, professional, and institutional claims
linked at the patient level. The study population was
identified by the following criteria: continuously enrolled
from 7/1/95 to 3/31/99, complete coverage, individuals
older than age 45 for women and age 65 for men with
fracture of interest, specific fracture by site; hip (820.0 to
821.39), vertebrae (806 to 806.91), and forearm (813.0
to 813.9x), past history of fracture and specific site by V
codes (13.5 and 15.5), chronic users of steroids (180
days exposure over a period of 24 months), history of
transplant (by CPT-4 and V codes), a diagnosis code of
733.0x, current history (in study period) of ICD-9 codes
for pathologic fractures 733.1 to 733.19, a family history
of musculoskeletal disease (V code 17.8), and individuals
with bone density studies (by CPT-4 codes). RESULTS:
Over 120 million claims were screened to stratify the
population (prior to 1997) into risk bands. We used
2,000 patients with current osteoporotic fractures to de-
velop and to verify a predictive model of fracture risk.
CONCLUSIONS: A claims based model identified high-
risk patients for fractures. Application of the model to
1999 data generated a list of patients for intervention.
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Economic models for highly active antiretroviral (HAART)
drug regimens used in HIV infection differ from other
models in that they must accommodate the results of
short trials, but yield relatively long-reaching predictions
of health outcomes, resource use, and costs, in an envi-
ronment where valid epidemiologic data are scarce. Stan-
dard Markov models were effective for short survival
times. With improved treatment options, survival of HIV
patients has been prolonged significantly. A methodolog-
ical consequence is that Markov models with fixed tran-
sition probabilities may no longer be reliable. Further-
more, the number and disparity of outcomes of interest,
such as surrogate marker changes, primary health out-
comes, treatment side effects, degree of adherence, and
viral resistance to subsequent regimens complicate Markov
approaches. OBJECTIVE: To compare two possible so-
lutions:1) a system of linked, staged Markov models; and
2) a hierarchical Monte Carlo simulation. METHODS:
Application of both methods to existing data. FIND-
INGS: The data requirement for the staged Markov sys-
tem depends on whether transitions are derived empiri-
cally or from theory. We found that approximately 27
exposure years are required per health state to ensure sta-
ble incidence densities, and that 12 model states health
states can capture both risk of progression and risk of
events observed in about 1500 patients over 3 years, but
that stable transition rates require at least 50 exposure
years per health state, and vary by antiretroviral experi-
ence. The hierarchical Monte Carlo model has more
modest requirements for data density, but depends on
long streams of uninterrupted observations from unique
patients. The strengths and weaknesses of these two ap-
proaches will be illustrated with data from the ritonavir
and ABT378 trials.
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Within pharmacoeconomic analysis, the generalizability
of results from one jurisdiction to another should not be
presumed. In general re-analysis of data for specific juris-
dictions is required. Thus, the lack of transparency in the
reporting of evaluations can limit their applicability to
decision-making. OBJECTIVES: First, to build a decision
analytic model to replicate the results from a stochastic
analysis of a US trial based economic analysis. Second, to
assess the transferability and generalizability of results to
the Canadian setting. METHODS: A decision analysis
model was developed to replicate results from the US
trial comparing the use of basiliximab and cyclosporin to
placebo and cyclosporin for renal transplant patients. We
determined the necessary parameters required to replicate
the study results and conducted re-analysis for the Cana-
dian setting. Data required related to clinical probabili-
ties, costs of treatments and treatment paths. RESULTS:
Results from the US study were replicated using the deci-
sion analytic model. The cyclosporin-basiliximab arm led
to the least cost path when compared to cyclosporin-pla-
cebo, with costs of $28,858 and $32,253 respectively,
approximating the results of the stochastic analysis of
$28,927 and $32,300. Further analysis was conducted
for the Canadian setting, and found similar results.
CONCLUSIONS: Where the criteria for geographic
transferability are satisfied it is possible to transfer the re-
sults of a clinical trial to other geographic locations.
However, it need not follow that results are generaliz-
able. In addition, when assessing the generalizability of
